Managing Uncontrolled Polycythemia Vera
Managing Uncontrolled Polycythemia Vera
June 2016
- A 49-year old male presents with headache, fatigue, and pain under his left ribs
- PMH includes depression and newly diagnosed hypertension
- Physical exam: BP, 160/90; abdominal exam reveals splenomegaly spleen palpable 6 cm below costal margin
- Laboratory values:
- Hb=20.7 g/L
- HCT= 59.4%
- WBC=10.2x109/L
- Platelets= 325 x109/L
- Bone marrow biopsy:
- MF-1 fibrosis and megakaryocytic hyperplasia with atypia
- JAK2-positive
- Patient was started on phlebotomy as needed and aspirin 81 mg
October 2016
- Patient returns 4 months later with continued headache and dizziness
- He has had 3 phlebotomies in the past 3 months
- Patient was started on hydroxyurea 1000 mg/day
January 2017
- Patient returns 3 months later with abdominal fullness, continued fatigue, difficulty concentrating, fever, and leg ulcer
- Laboratory values:
- Hb= 22.4 g/L
- HCT= 65.3%
- WBC=13.3x109/L
- Platelets=153x109/L
- Patient is started on ruxolitinib
NCCN guidelines indicate rusfertide for patients who are intolerant to phlebotomy or who receive frequent phlebotomy, regardless of risk status.
The FDA designation is for LYT-200 plus a hypomethylating agent for relapsed/refractory high-risk myelodysplastic syndromes.
The application for bezuclastinib in advanced systemic mastocytosisis is supported by data from the APEX trial.